|
|
|
|
|
|
Sponsors and Collaborators: |
Sunnybrook Health Sciences Centre Celgene Corporation |
Information provided by: | Sunnybrook Health Sciences Centre |
ClinicalTrials.gov Identifier: | NCT00744536 |
Angiogenesis increases in higher risk MDS patients and those with proliferative CMML. Angiogenesis is associated with increased risk of leukemic transformation and poorer prognoses. Low dose chemotherapy may have anti-angiogenic properties by targetting the genetically stable endothelial cells. Lenalidomide has been recently shown to be highly effective as monotherapy in low/low-intermediate risk MDS, particularly in the subgroup harboring a 5q- deletion. Lenalidomide has not been well studied in higher risk MDS although there are some reports of lenalidomide's efficacy in RAEB-T and AML. One potential mode of action of lenalidomide is inhibition of angiogenesis. The investigators hypothesize that by combining lenalidomide with low dose melphalan in higher risk MDS the investigators will more effectively block angiogenesis and achieve responses or hematologic improvement in MDS.
Condition | Intervention | Phase |
Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Angiogenesis |
Drug: Lenalidomide and melphalan |
Phase II |
MedlinePlus related topics: | Leukemia, Adult Acute Leukemia, Adult Chronic |
Drug Information available for: | Melphalan Melphalan hydrochloride Sarcolysin Lenalidomide CC 5013 |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: a Phase 2 Study" |
Estimated Enrollment: | 20 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental |
Drug: Lenalidomide and melphalan
Lenalidomide 10 mg po daily for 21d/28 Melphalan 2 mg po daily for 21d/28
|
Show Detailed Description |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Laboratory test results within these ranges:
Exclusion Criteria:
Contact: Cindy Davidson, RN | 416-480-5846 | cindy.davison@sunnybrook.ca |
Canada, Ontario | |||||
Odette Cancer Center | Recruiting | ||||
Toronto, Ontario, Canada, M4N3M5 | |||||
Contact: Rena J Buckstein, MD FRCPC 416-480-5847 rena.buckstein@sunnybrook.ca | |||||
Contact: Richard Wells, MD FRCPC PhD 416-480-6100 ext 7928 rwells@sri.utoronto.ca | |||||
Sub-Investigator: Richard Wells, MD FRCPC PhD | |||||
Sub-Investigator: Matthew Cheung, MD FRCPC |
Sunnybrook Health Sciences Centre |
Celgene Corporation |
Principal Investigator: | Rena J Buckstein, MD FRCPC | Odette Cancer Center |
Responsible Party: | Odette Cancer Center ( Rena Buckstein ) |
Study ID Numbers: | RV-MDS-PI-128 |
First Received: | August 29, 2008 |
Last Updated: | August 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00744536 |
Health Authority: | Canada: Canadian Institutes of Health Research; United States: Food and Drug Administration |
|
|
|
|
|
|